154 related articles for article (PubMed ID: 18308820)
1. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.
Taylor M; Currie A; Lloyd K; Price M; Peperell K
J Psychopharmacol; 2008 Mar; 22(2):128-31. PubMed ID: 18308820
[TBL] [Abstract][Full Text] [Related]
2. Health resource utilization associated with switching to risperidone long-acting injection.
Young CL; Taylor DM
Acta Psychiatr Scand; 2006 Jul; 114(1):14-20. PubMed ID: 16774656
[TBL] [Abstract][Full Text] [Related]
3. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use.
Taylor D; Fischetti C; Sparshatt A; Thomas A; Bishara D; Cornelius V
Acta Psychiatr Scand; 2009 Aug; 120(2):97-101. PubMed ID: 19207128
[TBL] [Abstract][Full Text] [Related]
4. Explicit review of risperidone long-acting injection prescribing practice.
Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
[TBL] [Abstract][Full Text] [Related]
5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
6. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):61-8. PubMed ID: 22776632
[TBL] [Abstract][Full Text] [Related]
7. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care.
Niaz OS; Haddad PM
Acta Psychiatr Scand; 2007 Jul; 116(1):36-46. PubMed ID: 17559599
[TBL] [Abstract][Full Text] [Related]
8. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
[TBL] [Abstract][Full Text] [Related]
9. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
[TBL] [Abstract][Full Text] [Related]
10. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
Taylor DM; Young CL; Mace S; Patel MX
J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592
[TBL] [Abstract][Full Text] [Related]
11. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.
Chan HW; Huang CY; Feng WJ; Yen YC
Psychiatry Clin Neurosci; 2015 Aug; 69(8):497-503. PubMed ID: 25781185
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
Wu DB; Lee EH; Chung WS; Chow DP; Lee VW; Wong MC; Lee KK
Psychiatry Res; 2013 Dec; 210(3):745-50. PubMed ID: 24012164
[TBL] [Abstract][Full Text] [Related]
13. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan.
Su KP; Chang HC; Tsai SJ; Yen FC; Tang CH
Value Health; 2009; 12 Suppl 3():S118-21. PubMed ID: 20586973
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
Olivares JM; Rodriguez-Morales A; Diels J; Povey M; Jacobs A; Zhao Z; Lam A; Villalobos Vega JC; Cuéllar JA; de Castro FJ; Quintero CM; Martíin JF; Domínguez P; Ojeda JL; Cortés SS; Cala FI; Marín CG; Castro LM; Duaso MA; Albarracín JR; Vergara GN; Benítez AF; Cleries FM; Pérez-Brian JM; Aragón AB; Navarro JC; Biedma JA; de Pedro RB; González JF; López ME; Moreno HD; López JA; Rodríguez EO; de Hoyos CM; Sacristán MP; Martín MD; Ballesteros EM; Rodríguez PA; Menéndez LF; Rivas RS; del Pino Cuadrado P; Lauffer JC; Solano JJ; Martínez JM; Solano FG; Rodríguez PG; Rodríguez JA; Cano TR; Fortacin MD; Lobeiras JM; Sampedro JM; Bravo AP; Pellicer AF; López MD; Liste JF; Fernández MR; Losada AC; Mendez RV; Romero SA; Blanco JJ; Bonaselt IT; Mahia MC; del Valle EF; Yañez PQ; Camarasa MG; Alonso JA; Mendez GF; Feliz FD; Lamela MA; Piñero MV; Alvarado PF; Gómez IL; Martín PF; Gómez JL; López AG; Jiménez AR; Nafs AE; Barquero NC; Ortiz RF; Noguera JL; Carrasco PR; Muñoz JM; Palma MM; Hortelano CM; Bonome LS; Sevilla JS; Juan JM; Ramos JM; Muñoz JL; Guisasola JE; Vazquez LS; Guerras FC; Nebot FJ; Fernández FJ; Nicolau AL; Subirats RC; Kidias MM; Navarro VF; García BF; del Rosal FM; de Vicente Muñoz T; Ballester JA; Lieb PM; Martel AD; Bea ER; Joaquim IG; Enjuanes FB; Piñol MB; Carbonell EF; Muñoz RM; Giribets CA; Sans LA; Blanco AS; Felipe MA; Muñoz PG; Villanueva AP; Arroyo MB; Borri RC; Fallada SM; Merola MC; Rodon EP; Palmes JR; Martínez EP; Catala JM; Coca AS; Ferrandiz FP; Paya EF; Caballero GI; Bonet AF; Figueras JF; Pagador PM; Garibo MM; Camo VP; Carrillo CS; Valero CP; Rebollo FJ; García Campayo J; Sala Ayma JM; Roig MM; de Uña Mateos MA; Bertolin RG; García AM; Mazo FJ; Velasco JL; Pérez LS; Casado CJ; Barba JJ; Diaz MC; Rubio JP; Mandoli AS; Herrero AU; Martínez AR; Serrano PS; Rodríguez EN; Montesinos JS; Macia JF; Mateos Marcos AM; Soto JV; Dumont MV; Pagan JP; Martínez VB; Santiuste de Pablos M; Delgado CE; Quiles MD; López FJ; Navarro PP; Torres AM; Ingles FJ; Arias-Camison JM; Manzano JC; Peña RV; Guitarte GP; Fontecilla HB; Romero JB; Gil RS; Lozano JM; Adanez LD; Zarranz Herrera-Oria I; Jiménez JP; Vaz FC; García OS; Anton CC; Casula RR; Hernandez MC; Escabias FT; Torresano JR; Pérez-Villamil AH; Estevez L; Figuero MA; Muñoz de Morales A; Calvin JL; Criado MD; Rodríguez VM; Ambrosolio EB; Madera PM; Alfaro GP; Vidal MM; Valtuille AG; Ruiz O; Cabornero GL; Echevarria Martínez de Bujo M; Mallen MJ; Puigros JS; Martorell AL; Forteza AC; Arrebola ER; Rodríguez de la Torre M; Saiz CG; Bardolet I Casas C; Linde ER; De Arce Cordon R; Molina EM; Carazo FJ; Romero JJ; Cano DV; Dorado MS; Velazquez SC; Sánchez AJ; Leon SO; Sánchez KP; Benitez MH; Zugarramurai AI; Contreras MA; De la Varga González M; Marín PB; Robina FG; García MS; Pérez FJ; Bros PC; Gómez AC; de Dios Molina Martín J; Perera JL; Averbach MC; Perera JL; Palancares EG; Gallego de Dios MT; Rojo CF; Iglesias SS; Merino MI; Mestre NP; Urdaniz AP; Sánchez JM; Seco RG; Muñoz JF; Agut MM; Lozano ML; Herguedas FM; Pena AT; García JV; Martínez AV; Sanz Granado OS; Fernández MA; Canseco JM; López PA; Martín MA; Barrio JA; Ubago JG; Bennassar MR; Díez JM; Fleta JL; Fortes FP; López CA; Medina O; Alvarez DF; Roca JM; Valladolid GR; Tavera JA; García-Castrillon Sales JA; Llordes IB; Melgarejo CA; Cañas de la Paz F; Callol VV; García MB; García JB; Leal FJ; Corrales EC; Iglesias ES; Gómez MA; Serrano GG; Chillarón EG; Aguado FJ; Castillo JJ; González AG; Vázquez JG; Peralvarez MB; Diaz MR; Mesa MY; Artiles FJ; Chao MA; Mesa MY; del Rosario Santana P; Escudero MA; Berenguer MM; Llacer JM; Berna JA; Ortiz JB; Pardell LT; Hernández-Alvarez de Sotomayor C; Méndez MR; Garate RC; Múgica BD; González MC; Domingo JP; Navarro CS; Vera GS; Cuquerella MA; Monzo JL; Boada PC; Pérez MF; Parrado EC; Sánchez JJ; Fernández JC;
Eur Psychiatry; 2009 Jun; 24(5):287-96. PubMed ID: 19195847
[TBL] [Abstract][Full Text] [Related]
15. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.
Taylor DM; Young C; Patel MX
Int J Neuropsychopharmacol; 2006 Dec; 9(6):685-94. PubMed ID: 16939663
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
17. Does Risperidone Long Acting Injectable Depot (RLAI) Reduce number of Admissions to Hospital.
Najim H; Pathak A; Pathak A
Psychiatr Danub; 2017 Sep; 29(Suppl 3):652-655. PubMed ID: 28953846
[TBL] [Abstract][Full Text] [Related]
18. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Gaebel W; Schreiner A; Bergmans P; de Arce R; Rouillon F; Cordes J; Eriksson L; Smeraldi E
Neuropsychopharmacology; 2010 Nov; 35(12):2367-77. PubMed ID: 20686456
[TBL] [Abstract][Full Text] [Related]
19. Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up.
Taylor D; Cornelius V
J Psychopharmacol; 2010 Jul; 24(7):995-9. PubMed ID: 19282424
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]